Changes in Lp-PLA2 Are Associated With Elevated Alanine Aminotransferase Levels: A Nested Case-Control Study in a Three-Year Prospective Cohort

Youngmin Han; Hye Jin  Yoo; Yeri Kim; Ximei Huang; Jong Ho  Lee; Minjoo Kim

doi:10.5937/scriptamed54-45869

Youngmin Han
Hye Jin Yoo
Yeri Kim
Ximei Huang
Jong Ho Lee
Minjoo Kim Hannam University

DOI: https://doi.org/10.5937/scriptamed54-45869

Sažetak

Background/Aim: Elevation in liver enzymes and hepatic fat may indicate a higher susceptibility to cardiovascular disease (CVD). This research sought to find anthropometric/biochemical variables significantly related to the alanine aminotransferase (ALT) increase in healthy populations.

Methods: 900 healthy subjects were included in a 3-year prospective cohort study. The initial screening revealed that 538 were found to be nondiabetic (fasting glucose < 126 mg/dL) and had normal ALT levels. Among them, 79 individuals with modestly elevated ALT levels after three years were assigned to the elevated ALT group. Of the remaining 459 participants, 241 subjects matched to the increased ALT group were the control group.

Results: After three years of follow-up, individuals with elevated ALT showed notably higher aspartate aminotransferase (AST), ALT, gamma-glutamyltransferase (γ-GT), high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A₂(Lp-PLA₂) activity, oxidised low-density lipoprotein (ox-LDL), urinary 8-epi-prostaglandin F_2α (8-epi-PGF₂_α) levels and brachial-ankle pulse wave velocity (ba-PWV) in comparison to the control group. Changes (Δ) in ALT showed a positive correlation with Δ AST, Δ gamma-GT, Δ hs-CRP, Δ Lp-PLA₂ activity, Δ ox-LDL, Δ urinary 8-epi-PGF₂_α and Δ ba-PWV. Furthermore, a direct positive link was observed between the Δ Lp-PLA₂ activity and Δ AST, Δ ox-LDL and Δ ba-PWV.

Conclusion: Increased Lp-PLA₂ activity and other CVD risk indicators were observed to have a pronounced association with elevated ALT levels. This mild ALT elevation could potentially contribute to chronic low-grade inflammation.

Reference

Westerbacka J, Cornér A, Tiikkainen M, Tamminen M, Vehkavaara S, Häkkinen AM, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004;47:1360–9.

Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006;22:437–43.

Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver 2001;21:17–26.

Xie Q, Lu S, Kuang M, He S, Yu C, Hu C, et al. Assessing the longitudinal association between the GGT/HDL-C ratio and NAFLD: a cohort study in a non-obese Chinese population. BMC Gastroenterol 2022;22(1):500. doi: 10.1186/s12876-022-02598-y.

Naidu BTK, Santosh Raju K, BhaskaraRao JV, Sunil Kumar N. Gamma-glutamyl transferase as a diagnostic marker of metabolic syndrome. Cureus 2023;15(6):e41060. doi: 10.7759/cureus.41060.

Kim HR, Han MA. Association between serum liver enzymes and metabolic syndrome in Korean adults. Int J Environ Res Public Health 2018;15(8):1658. doi: 10.3390/ijerph15081658.

Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010;52:1156–61.

Ikonomidis I, Kadoglou NN, Tritakis V, Paraskevaidis I, Dimas K, Trivilou P, et al. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease. Atherosclerosis 2014;234:34–41.

Kim M, Kim M, Han JY, Lee SH, Jee SH, Lee JH. The metabolites in peripheral blood mononuclear cells showed greater differences between patients with impaired fasting glucose or type 2 diabetes and healthy controls than those in plasma. Diab Vasc Dis Res 2017;14:130–8.

Lee YJ, Lee A, Yoo HJ, Kim M, No GM, Lee JH. Supplementation with the probiotic strain Weissella cibaria JW15 enhances natural killer cell activity in nondiabetic subjects. J Funct Foods 2018;48:153–8.

Dong MH, Bettencourt R, Barrett-Connor E, Loomba R. Alanine aminotransferase decreases with age: the Rancho Bernardo Study. PLoS One 2010;5:e14254. doi: 10.1371/journal.pone.0014254.

Oh RC, Hustead TR, Ali SM, Pantsari MW. Mildly elevated liver transaminase levels: causes and evaluation. Am Fam Physician 2017;96(11):709-15.

Feng LM, Feng GF, Chen Y. Evaluation of lipoprotein-associated phospholipase A2 in healthy Chinese Han adult serum. Lipids Health Dis 2014;13:6. doi: 10.1186/1476-511X-13-6.

Colak Y, Senates E, Ozturk O, Doganay HL, Coskunpinar E, Oltulu YM, et al. Association of serum lipoprotein-associated phospholipase A2 level with nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2012;10:103–9.

Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: The story continues. Med Res Rev 2020;40(1):79-134.

Nezos A, Skarlis C, Psarrou A, Markakis K, Garantziotis P, Papanikolaou A, et al. Lipoprotein-associated phospholipase A2: a novel contributor in Sjögren's syndrome-related lymphoma? Front Immunol 2021;12:683623. doi: 10.3389/fimmu.2021.683623.

Yao J, Zhao Y. Lp-PLA2 silencing ameliorates inflammation and autophagy in nonalcoholic steatohepatitis through inhibiting the JAK2/STAT3 pathway. PeerJ 2023;11:e15639. doi: 10.7717/peerj.15639.

Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25:193–7.

Chae JS, Kim OY, Paik JK, Kang R, Seo WJ, Jeong TS, et al. Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome. Atherosclerosis 2011;218(2):499-506.

Mouchlis VD, Hayashi D, Vasquez AM, Cao J, McCammon JA, Dennis EA. Lipoprotein-associated phospholipase A2: A paradigm for allosteric regulation by membranes. Proc Natl Acad Sci U S A. 2022;119(2):e2102953118. doi: 10.1073/pnas.2102953118.

Khan SA, Ilies MA. The Phospholipase a2 superfamily: structure, isozymes, catalysis, physiologic and pathologic roles. Int J Mol Sci 2023;24(2):1353. doi: 10.3390/ijms24021353.

Stafforini DM, Sheller JR, Blackwell TS, Sapirstein A, Yull FE, McIntyre TM, et al. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem 2006;281:4616–23.

Kriska T, Marathe GK, Schmidt JC, McIntyre TM, Girotti AW. Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides. J Biol Chem 2007;282:100–8.

Kono N, Inoue T, Yoshida Y, Sato H, Matsusue T, Itabe H, et al. Protection against oxidative stress-induced hepatic injury by intracellular type II platelet-activating factor acetylhydrolase by metabolism of oxidized phospholipids in vivo. J Biol Chem 2008;283:1628–36.

Xiong Z, Zhu C, Zheng Z, Wang M, Wu Z, Chen L, et al. Relationship between arterial stiffness assessed by brachial-ankle pulse wave velocity and coronary artery disease severity assessed by the SYNTAX score. J Atheroscler Thromb 2012;19:970–6.

Sugawara J, Hayashi K, Yokoi T, Cortez-Cooper MY, DeVan AE, Anton MA, et al. Brachial-ankle pulse wave velocity: an index of central arterial stiffness? J Hum Hypertens 2005;19:401–6.

Wu CF, Liu PY, Wu TJ, Hung Y, Yang SP, Lin GM. Therapeutic modification of arterial stiffness: An update and comprehensive review. World J Cardiol 2015;7:742–53.